



BioInvent signs production agreement with ITBMed

Lund, Sweden – 23 July 2018 – BioInvent International AB (OMXS: BINV) announces today that the Company has signed a production agreement with the Swedish biopharmaceutical company ITBMed AB. The production agreement is expected to generate revenue of at least SEK 17 million in 2018 and 2019.

“We look forward to manufacture ITBMed’s drug candidate for their late-stage clinical trials. Having our own production facility provides BioInvent great flexibility and efficiency in accelerating our proprietary immuno-oncology drug programs, while it also gives us an opportunity to generate near-term revenue from external partners”, **says Björn Frendéus, Acting CEO of BioInvent.**

Under the agreement, BioInvent will perform cGMP manufacturing of the anti-CD2 monoclonal antibody, Siplizumab, for ITBMed’s ongoing clinical trials.

“The development of our lead candidate, Siplizumab, is progressing as planned. Siplizumab is used as the key component in connection with transplanted organs to achieve tolerance and eliminate the need for long-term immunosuppressive treatment. BioInvent’s experience in cGMP antibody manufacturing will be valuable to bring Siplizumab into pivotal phase III clinical trials”, **says Erik Berglund, CEO of ITBMed.**

BioInvent’s manufacturing capabilities

The BioInvent manufacturing facility is compliant with Current Good Manufacturing Practice (cGMP) regulations and is fully based on disposable technology and can produce batches in sizes from 40 L to 1,000 L. The platform process ensures rapid and efficient process development and spans everything from cell line development to final release of drug substance for clinical trials. BioInvent offers a range of cell line development options that include a royalty free GS knocked CHO K1 cell line.

Notes to editors:

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company’s clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. The Company has a strategic research collaboration with Pfizer Inc. and BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Björn Frendéus
Acting CEO and CSO
+46 (0) 46 286 25 45
bjorn.frendeus@bioinvent.com

Hans Herklots
LifeSci Advisors
+41 79 598 71 49
hherklots@lifesciadvisors.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET, on 23 July, 2018.